Rituximab monotherapy in relapsed lymphocyte-predominant Hodgkin's lymphoma.
Nodular lymphocyte-predominant Hodgkin's lymphoma (NLPHL) accounts for approximately 5% of Hodgkin's lymphoma, presents with early-stage disease and has an indolent course. Treatment is not well established. We present a patient diagnosed with NLPHL and treated with Rituximab second-line therapy after chemotherapy.
Galán
Laura
L
Servicio de Oncología Médica, Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain.
Sánchez
Antonio C
AC
Cantos
Blanca
B
Provencio
Mariano
M
D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant; D005260:Female; D006689:Hodgkin Disease / Q000145:classification / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D008213:Lymphocyte Activation / Q000187:drug effects; D012008:Recurrence; D000069283:Rituximab
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab
J Clin Oncol. 1999 Mar;17(3):776-83
10071266
Blood. 2006 Nov 15;108(10):3295-301
16873669
Blood. 2008 Jan 1;111(1):109-11
17938252
Blood. 2004 Nov 1;104(9):2675-81
15231567
Blood. 2003 Jan 15;101(2):420-4
12509381
Blood. 2003 Jun 1;101(11):4285-9
12586628
J Clin Oncol. 2002 Oct 15;20(20):4261-7
12377971
Eur J Haematol Suppl. 2005 Jul;(66):106-10
16007877
Oncology. 2009;76(1):26-9
19033694
Curr Opin Oncol. 2009 Sep;21(5):397-400
19606035
Hematology Am Soc Hematol Educ Program. 2006;:266-72
17124071